ABSTRACT To investigate the effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy, we studied 14 patients at catheterization with a nonimaging scintillation probe before and after serial intravenous infusions of low-, medium-, and highdose verapamil (total dose 0.17 to 0.72 mg/kg). Percent change in radionuclide stroke counts after verapamil correlated well with percent change in thermodilution stroke volume (r = .87), and changes in diastolic and systolic counts were used to assess relative changes in left ventricular volumes after verapamil. Verapamil produced dose-related increases in end-diastolic counts (19 ± 9% increase; p < .001), end-systolic counts (91 ± 54% increase; p < .001), and stroke counts (7 ± 10% increase; p < .02). This was associated with a decrease in ejection fraction (83 ± 8% control, 73 ± 10% verapamil; p < .001) and, in the 10 patients with left ventricular outflow tract gradients, a reduction in gradient (62 + 27 mm Hg control, 32 ± 35 mm Hg verapamil; p < .01). The end-systolic pressure-volume relation was shifted downward and rightward in all patients, suggesting a negative inotropic effect. In 10 patients, left ventricular pressure-volume loops were constructed with simultaneous micromanometer pressure recordings and the radionuclide time-activity curve. In five patients, verapamil shifted the diastolic pressure-volume curve downward and rightward, demonstrating improved pressure-volume relations despite the negative inotropic effect, and also increased the peak rate of rapid diastolic filling. In the other five patients, the diastolic pressure-volume relation was unaltered by verapamil, and increased end-diastolic volumes occurred at higher end-diastolic pressures; in these patients, the peak rate of left ventricular diastolic filling was not changed by verapamil. The negative inotropic effects of intravenous verapamil are potentially beneficial in patients with hypertrophic cardiomyopathy by decreasing left ventricular contractile function and increasing left ventricular volume. Verapamil also enhances left ventricular diastolic filling and improves diastolic pressure-volume relations in some patients despite its negative inotropic effect.
THERAPY AND PREVENTION-HYPERTROPHIC CARDIOMYOPATHY undergoing diagnostic right and left heart catheterization at the National Heart, Lung and Blood Institute. There were seven men and seven women. The diagnosis of hypertrophic cardiomyopathy was based in each patient on M mode and twodimensional echocardiographic demonstration of a hypertrophied, nondilated left ventricle in the absence of another cardiac or systemic disease.6' 7 All patients had disproportionate thickening of the ventricular septum with respect to the posterior left ventricular free wall (septal-to-free wall ratio of 1.5 to 2.7, mean 2.0). Ventricular septal thickness ranged from 16 to 32 mm (mean 23). All patients were symptomatically limited (New York Heart Association functional classes III and IV) despite medical therapy. All cardiac medications were discontinued before catheterization. Propranolol was stopped at least 48 hr before catheterization, and verapamil at least 36 hr before catheterization. Informed consent was obtained before catheterization.
Hemodynamic measurements. Right and left heart catheterization was performed by standard techniques for our laboratory. Left ventricular pressures were measured by fluid-filled pigtail catheters (end hole only, no side holes) in four patients and micromanometer transducer-tipped catheters (Millar Instruments, Inc., Houston) in 10 patients. Catheter entrapment8 was excluded by the guidelines proposed by Wigle et al. 9 Cardiac output was measured with the right heart catheter by the thermodilution technique'0 (thermodilution cardiac output computer; Edwards Laboratories, Inc., Santa Ana, CA); for each cardiac output determination, the average of three measurements was computed. Left ventricular stroke volume was calculated from the cardiac output. Systemic blood pressure was monitored by means of a brachial artery catheter. Left ventricular end-systolic pressure was estimated by the dicrotic notch of the simultaneously recorded brachial artery pressure.
In the 10 patients studied with micromanometer catheters, left ventricular relaxation was assessed by computing the time constant (T) of left ventricular pressure fall after peak negative dP/dt. I I The logarithm of left ventricular pressure was plotted as a function of time every 5 msec for a total of 80 msec beginning at peak negative dP/cdt. T was calculated as the inverse of the slope of the exponential equation describing this relationship. In several patients, a single exponential function did not adequately describe the change in pressure with time; in these patients, biexponential fitting was used, with one time constant (TI) describing the first 40 msec after peak negative dP/dt and another (T2) describing the next 40 msec.12 Peak negative dP/dt was not used as an index of left ventricular relaxation because of the significant decrease in peak left ventricular pressure after verapamil. " I Contrast left ventriculography was performed in the right anterior oblique projection to assess the presence and severity of mitral regurgitation. In six patients left ventriculography was performed during a previous catheterization, and in the other eight patients ventriculography was performed at the completion of the radionuclide measurements. In five patients there was no mitral regurgitation. In the other nine patients, mild mitral regurgitation (1I to 2+) was present.
Radionuclide measurements. During placement of the right heart catheter, red blood cells were labeled in vivo with 15 to 20 mCi technetium-99m.'3 Ten minutes after administration of 99mTc, the patient underwent anticoagulation with heparin (5000 U, iv), and retrograde left heart catheterization was begun.
After equilibration of the tracer in the blood pool, and after placement of catheters in the pulmonary artery and left ventricle, the scintillation probe was positioned over the left ventricle. Nonimaging scintillation probe. The microprocessor-based scintillation probe system developed at the National Institutes of Health consists of a 7.5 cm diameter, 2.59 cm thick Nal crystal equipped with a high-sensitivity parallel-hole collimator permitVol. 68, No. 5, November 1983 ting counting rates in excess of 40,000/sec. 14 The nonimaging detector is interfaced to a microprocessor, which acquires, analyzes, and displays the scintillation data in real time. The linearity between counting rates and volume for the probe with parallel-hole collimation has been reported previously. ' Complete hemodynamic and radionuclide data at all three doses of verapamil were obtained in three patients. In a fourth patient, radionuclide data collection during low-and mediumdose verapamil infusions were incomplete, but all data were obtained during high-dose (V3) verapamil infusion in this patient. Of the remaining 10 patients, only one complete dose of verapamil was administered to three patients and two doses to seven patients. In these patients, the next highest verapamil infusion was either not begun or was discontinued before measurements were made because of second-degree atrioventricular block (one patient), decrease in systolic blood pressure greater than 25 mm Hg compared with the control blood pressure (four patients), decrease in systolic arterial pressure below 85 mm Hg (four patients), or increase in pulmonary wedge pressure above 30 mm Hg (one patient).
Variability of radionuclide measurements. During the course of the catheterization studies, it was occasionally necessary to move and then reposition the probe over the left ventricle (e.g., to perform background measurements). To ensure that reproducible measurements could be achieved by the probe after repositioning, we performed probe studies in 10 other patients undergoing routine Anger camera studies in the Nuclear Cardiology Laboratory. The diagnosis in these patients were coronary artery disease (four patients), hypertrophic cardiomyopathy (two patients), aortic stenosis (two patients), aortic regurgitation (one patient), and restrictive cardiomyopathy (one patient). These patients underwent probe repositioning studies in which 10 consecutive probe measurements were made. During the first measurement, the position of the probe over the left ventricle was marked on the patient's chest. Between each measurement the probe was moved away from the chest and then repositioned over the left ventricle. End-diastolic counts, end-systolic counts, stroke counts, and ejection fraction were computed for each of the 10 studies per patient. Background was measured in each patient after the first and after the tenth left ventricular measurements. Changes in left ventricular counts and background counts with time were corrected for physical decay of the isotope.
Statistical methods. The effects of verapamil on left ventricular hemodynamics and radionuclide measurements were analyzed by the paired t test, comparing control and the highest dose of verapamil achieved for each patient. A repeat analysis was made comparing control and low-dose (V1) verapamil.
Results
Control measurements. Hemodynamic data obtained during control conditions for the 14 Among the 10 patients in whom instantaneous left ventricular pressure-volume (counts) data were obtained, the diastolic pressure-volume curve was shifted downward and rightward by verapamil in five patients, reflecting improved pressure-volume relations (figure 7). In this subgroup, peak left ventricular filling rate, normalized for end-diastolic volume, increased after verapamil in all five (3.7 ± 1.0 EDV/sec control, 4.6 ± 0.6 EDV/sec verapamil; p < .01) and the time constant of relaxation decreased in all five ( The probe reproducibility studies in our laboratory indicate no inherent change in background activity with time. Although apparent increases in left ventricular counts (and reduction in apparent ejection fraction) might occur on the basis of increased background activity after acute verapamil administration, such increases were not observed. We have also observed no increases in background activity during Anger camera studies of oral verapamil therapy in over 50 patients with hypertrophic cardiomyopathy.4 23 Finally, the uncertainty of background effects on quantitative left ventricular volume and function were minimized by determining background activity from Anger camera studies'4 at the completion of the probe study in the catheterization laboratory.
Effect of verapamil in hypertrophic cardiomyopathy.
The left ventricle of patients with hypertrophic cardiomyopathy is characterized by myocardial hypertrophy, In a second subgroup of patients in our study, however, improved diastolic function could not be documented. In these five patients the diastolic pressure-volume curve was not altered by verapamil and increased diastolic volumes occurred at higher diastolic pressures (figure 8). The time constant of relaxation increased in these five patients, and the peak rate of ventricular filling (normalized for end-diastolic volume) decreased in four. In one patient an increased rate of diastolic filling developed in the setting of alarming increases in left ventricular end-diastolic pressure and pulmonary capillary wedge pressure. Presumably, an elevated left atrial pressure, with resulting increased driving pressures across the mitral valve, served to increase the rate of rapid ventricular filling in this patient. 32 It cannot be ascertained from our study whether verapamil actually had no 
